Meta-iodobenzylguanidine in children

Area of Science:

• Nuclear medicine
• Pediatric oncology
• Radiopharmaceutical imaging

Background:

• Meta-iodobenzylguanidine (MIBG) concentrates in neurosecretory granules of neural crest-derived tissues.
• MIBG scintigraphy demonstrates high sensitivity and specificity for neuroblastoma and pheochromocytoma.
• Normal MIBG uptake occurs in salivary glands, myocardium, liver, and GI tract.

Purpose of the Study:

• To review the established role and emerging applications of MIBG in pediatric neural tumors.
• To discuss current controversies and future directions in MIBG imaging and therapy.

Main Methods:

• Review of MIBG's diagnostic utility in neuroblastoma and pheochromocytoma.
• Evaluation of MIBG labeled with iodine-123 (123I) and iodine-131 (131I).
• Discussion of MIBG's potential in detecting bone and bone marrow involvement.

Main Results:

• MIBG imaging shows high sensitivity and specificity for neuroblastoma and pheochromocytoma.
• 123I-MIBG offers improved image quality and reduced radiation dose compared to 131I-MIBG.
• MIBG can detect bone and bone marrow involvement missed by other imaging modalities.

Conclusions:

• MIBG is a crucial imaging agent for pediatric neural tumors, routinely used in many centers.
• Further research is needed to optimize MIBG's therapeutic applications in advanced neural crest tumors.
• Controversies include optimal radioisotope labeling, role of bone scans, and early therapeutic intervention.